Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Orafti Synergy1 is a patented prebiotic composition consisting of a specific blend of short-chain oligofructose and long-chain inulin. Developed by BENEO, it is designed to selectively stimulate the growth of beneficial gut bacteria, particularly *Bifidobacterium*, throughout the entire length of the colon due to the varying fermentation rates of its components. This modulation of the gut microbiome is associated with improved gut barrier function, enhanced mineral absorption (such as calcium), and reduced systemic inflammation. In clinical research, Orafti Synergy1 is often evaluated for its potential to mitigate metabolic and inflammatory markers in conditions like chronic kidney disease, type 2 diabetes, and obesity, frequently as part of a symbiotic formulation with probiotics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Orafti Synergy1.